 Outlook Therapeutics, Inc. OTLK the Company, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into agreements with BioLexis Pte. Ltd. BioLexis, its largest stockholder, and MTTR, LLC MTTR, its development partner for ONS-5010, to better align the interests of all parties with the Companys common stockholders and support the continued development of ONS-5010. 